Skip to main content

Table 1 HIV testing, CD4 cell count assessment, and ARV regimens initiated during pregnancy in Rwanda, from July 2006 through to December 2008 (N= 32 sites)

From: Comparing two service delivery models for the prevention of mother-to-child transmission (PMTCT) of HIV during transition from single-dose nevirapine to multi-drug antiretroviral regimens

 

2006 (Jul-Dec)

N (%)

2007

N (%)

2008

N (%)

Total

N (%)

p**

(2007 vs. 2008)

Total number of sites

14

19

32

-

-

   Full package

5 (35.7%)

15 (79%)

18 (56%)

-

-

Counseling and testing of pregnant women in ANC:

     

   First ANC visit

4,520

15,469

20,685

40,674

-

   Known to be HIV positive

NA

135 (0.9%)

291 (1.4%)

426 (1%)

-

   Tested for HIV

4,452 (98%)

15,231 (98%)

20,564 (99%)

40,247 (99%)

<0.0001

   Tested HIV positive

234 (5%)

741 (5%)

647 (3%)

1,622 (4%)

<0.0001

Partner counseling and HIV testing

NA

8,652 (57%)

15,463 (75%)

24,115 (67%)$

<0.0001

CD4 cell count assessment during pregnancy

     

   Total HIV positive in ANC

234

876

938

2,048

-

   Screened for CD4 cell counts¶

140 (60%)

610 (70%)

658 (70%)

1,408 (69%)

0.81

   Received CD4 cell count results¶¶

NA

564 (92%)

647 (98%)

1,211 (96%)$

<0.0001

   CD4 cell counts < 350 cells/mm3

NA

132 (23%)

160 (25%)

292 (24%)$

0.59

Enrolment of HIV positive women into care and treatment

NA

180/443 (41%)@

564/938 (60%)

744/1381 (54%)$

-

HAART initiation for women with CD4 cell counts < 350 cells/mm3

NA

114/132 (86%)

127/160 (79%)

241/292 (83%)$

0.12

Total HIV positive in ANC

234

876

938

2,048

 

All ARV regimens initiated during pregnancy

155 (66%)

667 (76%)

638 (68%)

1460 (71%)

 

   Dual (AZT/NVP) prophylaxis

55 (35.5%)

386 (58%)

403 (63%)

844 (58%)

 

   HAART for life

NA

114 (17%)

127 (20%)

241 (16%)

 

   sd-nvp only

100 (64.5%)

34 (5%)

21 (3%)

155 (11%)

 

   Short-course HAART

NA

133 (20%)

87 (14%)

220 (15%)

 

More efficacious ARV regimens (dual ARV, or HAART for life or sc-HAART)

55 (35.5%)

633 (95%)

617 (97%)

1325 (89%)

 
  1. $ Percentage calculated based on 2007 and 2008 data only.
  2. NA indicates data not available or not routinely reported in the program monthly report.
  3. ¶ Indicates the number of HIV+ pregnant women giving blood for CD4 testing and includes women of known HIV+ status.
  4. ¶¶ Indicates the number of HIV+ women receiving CD4 results in a given period and might include women screened in a previous time period. This number is used as a denominator to compute the proportion of women with CD4 cell counts < 350 cells/mm3, which reflects the number of women whose results were available and who returned for enrolment in health regimens and subsequent HAART initiation.
  5. @ Data available only for the period from July - December 2007. The denominator was limited to the total number of HIV positive women during the same period.
  6. ** Chi-square test, two-sided p-value comparing the 2007 to 2008 data only.